IBIO
HEALTHCAREiBio Inc
$1.77+0.16 (+9.94%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving IBIO Today?
No stock-specific AI insight has been generated for IBIO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.56$3.82
$1.77
Fundamentals
Market Cap$64M
P/E Ratio—
EPS$-1.00
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume1.9M
Avg Volume (10D)—
Shares Outstanding36.1M
IBIO News
20 articles- iBio (IBIO) Receives Regulatory Clearance to Initiate Phase 1 Trial of IBIO-600Yahoo Finance·Apr 24, 2026
- iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close “Trust Gap”Marketbeat·Apr 8, 2026
- iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in AustraliaYahoo Finance·Apr 8, 2026
- iBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3Marketbeat·Mar 20, 2026
- iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Yahoo Finance·Mar 16, 2026
- iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight LossYahoo Finance·Mar 9, 2026
- iBio to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 24, 2026
- iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate UpdateYahoo Finance·Feb 10, 2026
- CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?Yahoo Finance·Feb 3, 2026
- iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseYahoo Finance·Feb 2, 2026
- iBio Announces $26 Million Private PlacementYahoo Finance·Jan 9, 2026
- iBio Insiders Placed Bullish Bets Worth US$655.0kYahoo Finance·Dec 20, 2025
- BC-Most Active StocksYahoo Finance·Dec 10, 2025
- iBio to Participate in the 8th Annual Evercore Healthcare ConferenceYahoo Finance·Nov 24, 2025
- iBio, Inc. (IBIO) Reports Q1 LossYahoo Finance·Nov 12, 2025
- iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 12, 2025
- iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight MaintenanceYahoo Finance·Oct 30, 2025
- iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation ConferenceYahoo Finance·Oct 23, 2025
- iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025Yahoo Finance·Oct 21, 2025
- iBio Full Year 2025 Earnings: US$1.75 loss per share (vs US$4.03 loss in FY 2024)Yahoo Finance·Sep 6, 2025
All 20 articles loaded
Price Data
Open$1.61
Previous Close$1.61
Day High$1.78
Day Low$1.60
52 Week High$3.82
52 Week Low$0.56
52-Week Range
$0.56$3.82
$1.77
Fundamentals
Market Cap$64M
P/E Ratio—
EPS$-1.00
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume1.9M
Avg Volume (10D)—
Shares Outstanding36.1M
About iBio Inc
iBio, Inc., a biotech company, provides contract development and manufacturing services to outside partners and customers in the United States. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—